Quanterix Dirección

Dirección controles de criterios 2/4

El CEO de Quanterix's es Masoud Toloue , nombrado en Apr 2022, tiene una permanencia de 2.08 años. compensación anual total es $5.44M, compuesta por 11.3% salario y 88.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.45% de las acciones de la empresa, por valor de $2.80M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 4 años, respectivamente.

Información clave

Masoud Toloue

Chief Executive Officer (CEO)

US$5.4m

Compensación total

Porcentaje del salario del CEO	11.3%
Permanencia del CEO	2.1yrs
Participación del CEO	0.5%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Apr 14

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Apr 05

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 03

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Oct 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Masoud Toloue en comparación con los beneficios de Quanterix?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$5m	US$615k	-US$32m
Sep 30 2023	n/a	n/a	-US$39m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$541k	-US$97m
Sep 30 2022	n/a	n/a	-US$98m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$66m
Dec 31 2021	US$4m	US$279k	-US$58m

Compensación vs. Mercado: La compensación total de Masoud($USD5.44M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.43M).

Compensación vs. Ingresos: La compensación de Masoud ha aumentado mientras la empresa no es rentable.

CEO

Masoud Toloue (42 yo)

2.1yrs

Permanencia

US$5,435,274

Compensación

Dr. Masoud Toloue, Ph D., serves as Chief Executive Officer, President and Director of Quanterix Corporation since April 25, 2022. He served as Head of Diagnostics Business of Quanterix Corporation until A...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Masoud Toloue	President	2.1yrs	US$5.44m	0.45% $ 2.8m
David Walt	Co-Founder	17.3yrs	US$247.25k	3.76% $ 23.2m
Vandana Sriram	CFO & Treasurer	less than a year	US$1.35m	sin datos
Daniel Pikora	Chief Operating Officer	1.7yrs	sin datos	sin datos
David Duffy	Senior VP of Research & Development and CTO	11.2yrs	US$511.93k	sin datos
Alexandra Phillips	Senior VP & Chief Information Officer	no data	sin datos	sin datos
Laurie Churchill	Senior VP	1.3yrs	sin datos	sin datos
Naren Bhat	Senior Vice President of Corporate Development & Strategy	less than a year	sin datos	sin datos
Erica Bell	Chief People Officer	2.3yrs	sin datos	sin datos
Mark Roskey	Chief Science & Collaboration Officer	9.7yrs	US$1.28m	0% $ 0
Darrin Crisitello	Senior VP & Chief Commercial Officer	3.3yrs	sin datos	sin datos

2.2yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de QTRX se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Masoud Toloue	President	2.1yrs	US$5.44m	0.45% $ 2.8m
David Walt	Co-Founder	17.1yrs	US$247.25k	3.76% $ 23.2m
Paul Meister	Independent Director	10.7yrs	US$259.96k	0.76% $ 4.7m
William P. Donnelly	Independent Director	less than a year	US$418.58k	0.056% $ 345.2k
Martin Madaus	Independent Chairman	13.5yrs	US$275.00k	0.74% $ 4.5m
Robert Corn	Member of Scientific Advisory Board	15.5yrs	sin datos	sin datos
Sarah Elizabeth McConnell	Independent Director	4.8yrs	US$259.96k	0.11% $ 655.6k
John Ramsey	Member of Scientific Advisory Board	no data	sin datos	sin datos
Larry Kricka	Member of Scientific Advisory Board	no data	sin datos	sin datos
Brian Blaser	Independent Director	1.3yrs	US$445.79k	0.014% $ 86.5k
Karen Flynn	Independent Director	1.9yrs	US$251.63k	0.038% $ 236.0k
Laurie Olson	Independent Director	3.1yrs	US$255.00k	0.028% $ 173.7k

4.0yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de QTRX se considera experimentada (3.9 años de antigüedad promedio).

Quanterix Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Director recently bought US$502k worth of stock

High number of new directors

Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors

Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023

Recent updates

Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 9.7% to US$29.80

New minor risk - Shareholder dilution

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Year 2024

Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023

Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 11% to US$33.25

New minor risk - Shareholder dilution

Quanterix Corporation Revises Earnings Guidance for the 2023

Quanterix Corporation Revises Earnings Guidance for the 2023

New major risk - Revenue and earnings growth

Quanterix Corporation to Report Q3, 2023 Results on Nov 06, 2023

Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Price target increased by 9.7% to US$31.00

Director recently bought US$502k worth of stock

High number of new directors

Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors

Consensus estimates of losses per share improve by 20%

Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q2, 2023 Results on Aug 08, 2023

Quanterix Corporation Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$15.25

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Brian Blaser to Board of Directors

Quanterix Corporation Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease Conference

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September 30, 2022

Quanterix Corporation to Report Q3, 2022 Results on Nov 08, 2022

Quanterix Corporation: Selling For Less Than Cash Value

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Daniel Pikora as Chief Operating Officer

Quanterix stock gains after insider buys reported by CEO and CFO

Consensus forecasts updated

Independent Director recently bought US$2.0m worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Quanterix Corporation Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

Quanterix Corporation to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$34.50

Quanterix Corporation Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S

Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022

President recently sold US$85k worth of stock

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Quanterix Corporation Announces Resignation of Dawn Mattoon as Senior Vice President, Diagnostics, Effective July 10, 2022

Consensus forecasts updated

Price target decreased to US$45.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q1, 2022 Results on May 10, 2022

Quanterix Corporation, Annual General Meeting, Jun 23, 2022

Quanterix Corporation Grants Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

Quanterix Corporation announced that it has received funding from Alzheimers Drug Discovery Foundation

We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely

Consensus forecasts updated

Quanterix Announces Executive Leadership Succession Plan, Effective April 25, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind